Shares of Intra-Cellular Therapies Inc (ITCI, Financial) fell 3.18% in mid-day trading on Sep 23. The stock reached an intraday low of $74.94, before recovering slightly to $75.14, down from its previous close of $77.61. This places ITCI 11.49% below its 52-week high of $84.89 and 65.14% above its 52-week low of $45.50. Trading volume was 85,961 shares, 14.4% of the average daily volume of 596,522.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Intra-Cellular Therapies Inc (ITCI, Financial) is $95.84 with a high estimate of $130.00 and a low estimate of $74.00. The average target implies an upside of 27.55% from the current price of $75.14. More detailed estimate data can be found on the Intra-Cellular Therapies Inc (ITCI) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Intra-Cellular Therapies Inc's (ITCI, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Intra-Cellular Therapies Inc (ITCI, Financial) in one year is $194.35, suggesting a upside of 158.65% from the current price of $75.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Intra-Cellular Therapies Inc (ITCI) Summary page.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
